{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:27:17Z","timestamp":1787023637947,"version":"build-2736575974"},"reference-count":65,"publisher":"Impact Journals, LLC","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,5,10]]},"DOI":"10.18632\/oncotarget.3544","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T02:34:56Z","timestamp":1442284496000},"page":"10712-10727","source":"Crossref","is-referenced-by-count":32,"title":["Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic"],"prefix":"10.18632","volume":"6","author":[{"given":"Siddik","family":"Sarkar","sequence":"first","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget A.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ning","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Dash","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Chandrasekharpur, Bhubaneswar, Orissa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swadesh K.","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luni","family":"Emdad","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Klibanov","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pellecchia","sequence":"additional","affiliation":[{"name":"Infectious and Inflammatory Disease Center, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanand","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"},{"name":"VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"1","volume-title":"Cancer Facts and Figures 2013","author":"American Cancer Society","year":"2013"},{"issue":"4","key":"2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0305-7372(03)00013-6","article-title":"Bisphosphonates and radiation therapy for palliation of metastatic bone disease","volume":"29","author":"Hoskin","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"4","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Nemunaitis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"5","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"Henderson","year":"2001","journal-title":"Cancer Res"},{"issue":"12","key":"6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/gt.2008.72","article-title":"Gene therapy progress and prospects cancer: oncolytic viruses","volume":"15","author":"Kirn","year":"2008","journal-title":"Gene Ther"},{"issue":"3","key":"7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/mt.2008.70","article-title":"Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop","volume":"16","author":"Kirn","year":"2008","journal-title":"Mol Ther"},{"issue":"12","key":"9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.cgt.7700542","article-title":"Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes","volume":"9","author":"Kuhn","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"10","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/0008-5472.CAN-07-0195","article-title":"Eradication of therapy-resistant human prostate tumors using a cancer terminator virus","volume":"67","author":"Fisher","year":"2007","journal-title":"Cancer Res"},{"issue":"39","key":"11","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0506837102","article-title":"Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice","volume":"102","author":"Fisher","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1566524013666131118110827","article-title":"Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus","volume":"14","author":"Fisher","year":"2014","journal-title":"Curr Mol Med"},{"issue":"7","key":"13","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2174\/1566524011313070008","article-title":"Chemoprevention gene therapy (CGT): novel combinatorial approach for preventing and treating pancreatic cancer","volume":"13","author":"Fisher","year":"2013","journal-title":"Curr Mol Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-398342-8.00001-X","article-title":"Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes","volume":"115","author":"Fisher","year":"2012","journal-title":"Adv Cancer Res"},{"issue":"6","key":"15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ymthe.2004.08.020","article-title":"Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism","volume":"10","author":"Ekmekcioglu","year":"2004","journal-title":"Mol Ther"},{"issue":"51","key":"16","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1038\/sj.onc.1208911","article-title":"Unique aspects of mda-7\/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7\/IL-24 protein by normal cells","volume":"24","author":"Fisher","year":"2005","journal-title":"Oncogene"},{"issue":"19","key":"17","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1158\/0008-5472.CAN-05-1261","article-title":"Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice","volume":"65","author":"Fisher","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jcb.22075","article-title":"Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status","volume":"106","author":"Cong","year":"2009","journal-title":"J Cell Biochem"},{"issue":"28","key":"19","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1038\/onc.2011.496","article-title":"Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61","volume":"31","author":"Shevde","year":"2012","journal-title":"Oncogene"},{"issue":"31","key":"20","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1038\/onc.2010.194","article-title":"Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1","volume":"29","author":"Fisher","year":"2010","journal-title":"Oncogene"},{"issue":"16","key":"21","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1046\/j.1432-1033.2003.03723.x","article-title":"Regulation of Cyr61\/CCN1 gene expression through RhoA GTPase and p38MAPK signaling pathways","volume":"270","author":"Chaqour","year":"2003","journal-title":"Eur J Biochem"},{"issue":"2","key":"22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/mt.2009.252","article-title":"Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach","volume":"18","author":"Claudio","year":"2010","journal-title":"Mol Ther"},{"issue":"21","key":"23","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1073\/pnas.1100769108","article-title":"Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7\/IL-24-mediated toxicity","volume":"108","author":"Pellecchia","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/RLI.0b013e3182034fed","article-title":"Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent","volume":"46","author":"Rychak","year":"2011","journal-title":"Invest Radiol"},{"issue":"2","key":"25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2009.08.001","article-title":"Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow","volume":"140","author":"Ley","year":"2009","journal-title":"J Control Release"},{"issue":"20 Pt 1","key":"26","first-page":"6116","article-title":"Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy","volume":"12","author":"Igawa","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"7","key":"27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1535-7163.MCT-08-0333","article-title":"Natural BH3 mimetic (\u2212)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa","volume":"7","author":"Xu","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"28","first-page":"28","article-title":"An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins","volume":"1","author":"Pellecchia","year":"2011","journal-title":"Front Oncol"},{"issue":"9","key":"29","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/pros.21501","article-title":"Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness","volume":"72","author":"Getzenberg","year":"2012","journal-title":"Prostate"},{"issue":"7","key":"30","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1128\/MCB.10.7.3569","article-title":"Expression of cyr61, a growth factor-inducible immediate-early gene","volume":"10","author":"Lau","year":"1990","journal-title":"Mol Cell Biol"},{"issue":"8","key":"31","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/nar\/29.8.1661","article-title":"PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells","volume":"29","author":"Fisher","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"5B","key":"32","first-page":"1841","article-title":"Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells","volume":"15","author":"Fisher","year":"1995","journal-title":"Anticancer Res"},{"issue":"1","key":"33","first-page":"5","article-title":"Expression of the transformed phenotype induced by diverse acting viral oncogenes mediates sensitivity to growth suppression induced by caffeic Acid phenethyl ester (cape)","volume":"5","author":"Fisher","year":"1994","journal-title":"Int J Oncol"},{"issue":"11","key":"34","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1073\/pnas.79.11.3527","article-title":"Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF)","volume":"79","author":"Ginsberg","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1073\/pnas.0409141102","article-title":"Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter","volume":"102","author":"Fisher","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"36","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/cddis.2010.18","article-title":"A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy","volume":"1","author":"Pellecchia","year":"2010","journal-title":"Cell Death Dis"},{"issue":"5","key":"37","first-page":"1567","article-title":"Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers","volume":"148","author":"Reed","year":"1996","journal-title":"Am J Pathol"},{"issue":"12","key":"38","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-10-0563","article-title":"Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7\/IL-24, an IL-10-related cytokine","volume":"70","author":"Fisher","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/cbt.2.4.422","article-title":"mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cellsvia JNK signaling","volume":"2","author":"Dent","year":"2003","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Huang","year":"2005","journal-title":"Genes Dev"},{"issue":"4","key":"41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.cgt.7701022","article-title":"Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins","volume":"14","author":"Seymour","year":"2007","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cgt.2009.91","article-title":"Enhanced delivery of mda-7\/IL-24 using a serotype chimeric adenovirus (Ad. 5\/3) improves therapeutic efficacy in low CAR prostate cancer cells","volume":"17","author":"Fisher","year":"2010","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"43","first-page":"34","article-title":"Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad. 5\/3-CTV)","volume":"229","author":"Fisher","year":"2014","journal-title":"J Cell Physiol"},{"issue":"22","key":"44","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.1158\/0008-5472.CAN-05-3127","article-title":"Is mda-7\/IL-24 a \u201cmagic bullet\u201d for cancer?","volume":"65","author":"Fisher","year":"2005","journal-title":"Cancer Res"},{"issue":"5","key":"45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cytogfr.2010.08.004","article-title":"mda-7\/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity","volume":"21","author":"Sarkar","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1535-6108(03)00197-1","article-title":"Myc-driven murine prostate cancer shares molecular features with human prostate tumors","volume":"4","author":"Sawyers","year":"2003","journal-title":"Cancer Cell"},{"issue":"12","key":"47","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/hum.2004.15.1157","article-title":"The innate immune response to adenovirus vectors","volume":"15","author":"Muruve","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"6","key":"48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ymthe.2004.08.015","article-title":"Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies","volume":"10","author":"Amalfitano","year":"2004","journal-title":"Mol Ther"},{"issue":"56","key":"49","first-page":"46","article-title":"Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic","volume":"11","author":"Fisher","year":"2011","journal-title":"Discov Med"},{"issue":"52","key":"50","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1038\/sj.onc.1209037","article-title":"Oncolytic viral therapies - the clinical experience","volume":"24","author":"Martuza","year":"2005","journal-title":"Oncogene"},{"key":"51","first-page":"1","article-title":"Applications of viruses for cancer therapy","volume":"115","author":"Fisher","year":"2012","journal-title":"Adv Cancer Res"},{"key":"52","article-title":"Gene therapies for cancer: strategies, challenges and successes","author":"Fisher","year":"2014","journal-title":"J Cell Physiol"},{"issue":"1","key":"53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Wilding","year":"2006","journal-title":"Mol Ther"},{"issue":"4","key":"54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cgt.7701117","article-title":"Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I\/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region","volume":"15","author":"Essand","year":"2008","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4161\/auto.7.9.16163","article-title":"Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7\/interleukin-24 (mda-7\/IL-24)","volume":"7","author":"Fisher","year":"2011","journal-title":"Autophagy"},{"issue":"1","key":"56","first-page":"59","article-title":"Functional domains of CCN1 (Cyr61) regulate breast cancer progression","volume":"33","author":"Koeffler","year":"2008","journal-title":"Int J Oncol"},{"issue":"4","key":"57","first-page":"371","article-title":"Virus combinations and chemotherapy for the treatment of human cancers","volume":"10","author":"Reid","year":"2008","journal-title":"Curr Opin Mol Ther"},{"issue":"1","key":"58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1566523044577988","article-title":"Replicative oncolytic herpes simplex viruses in combination cancer therapies","volume":"4","author":"Van Meir","year":"2004","journal-title":"Curr Gene Ther"},{"issue":"10","key":"59","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1517\/13543784.2011.609167","article-title":"Targeting Mcl-1 for the therapy of cancer","volume":"20","author":"Wu","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"60","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.onc.1203424","article-title":"Regulation of mda-7 gene expression during human melanoma differentiation","volume":"19","author":"Fisher","year":"2000","journal-title":"Oncogene"},{"issue":"28","key":"61","doi-asserted-by":"crossref","first-page":"9763","DOI":"10.1073\/pnas.0804089105","article-title":"Autocrine regulation of mda-7\/IL-24 mediates cancer-specific apoptosis","volume":"105","author":"Fisher","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ymthe.2004.09.019","article-title":"Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study","volume":"11","author":"Nemunaitis","year":"2005","journal-title":"Mol Ther"},{"issue":"1","key":"63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymthe.2004.09.021","article-title":"Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7\/IL24): biologic outcome in advanced cancer patients","volume":"11","author":"Chada","year":"2005","journal-title":"Mol Ther"},{"issue":"3","key":"64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.taap.2006.11.021","article-title":"Melanoma differentiation associated gene-7\/interleukin-24 (mda-7\/IL-24): novel gene therapeutic for metastatic melanoma","volume":"224","author":"Nemunaitis","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"65","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/RLI.0b013e31824bd237","article-title":"Insonation of targeted microbubbles produces regions of reduced blood flow within tumor vasculature","volume":"47","author":"Ferrara","year":"2012","journal-title":"Invest Radiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T07:13:11Z","timestamp":1589353991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":65,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,5,10]]}},"alternative-id":["3544","25926554"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3544","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}